NCT03992430 / 2018-001762-42: A Study to Compare Safety and Efficacy of a High Dose of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Eteplirsen, AVI-4658, EXONDYS 51, EXONDYS | Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. | Muscular Dystrophy, Duchenne | 11/24 | 11/24 | | |
NCT04179409: A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications. |
|
|
| Completed | 2 | 3 | US | Amondys 45, SRP-4045, Casimersen, Exondys 51, Eteplirsen, AVI-4658, Vyondys 53, SRP-4053, Golodirsen | Kevin Flanigan, Sarepta Therapeutics, Inc. | Duchenne Muscular Dystrophy | 09/21 | 09/23 | | |
MOMENTUM, NCT04004065 / 2019-000601-77: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment |
|
|
| Active, not recruiting | 2 | 62 | Europe, Canada, US | Vesleteplirsen, SRP-5051 | Sarepta Therapeutics, Inc. | Duchenne Muscular Dystrophy | 10/23 | 01/29 | | |
